Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
50
¥ million (increase in the operating profit target for the fiscal year ending May 2027)Wording
Conditional
How definitive the wording is.Items stated in the management plan
Partially revisedNet Sales0.0%
基準 33,000Target33,000million
Operating profit0.0%
基準 2,028Target2,028million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
Operating profit marginNot disclosed → 4.0% (plan for the fiscal year ending May 2027)
Net income for the current fiscal yearNot disclosed → 550 (plan for the fiscal year ending May 2027)
Only the target level is shown because the current level for comparison was not provided.What happened to the previous planRevenue of 23,600, EBITDA of 1,015 and operating profit of 327 (initial forecasts for the fiscal year ending May 2026) → Revenue of 22,235, EBITDA of 964 and operating profit of 312 (actual results for the fiscal year ending May 2026)（Achievement rates: revenue 94.2%, EBITDA 95.0% and operating profit 95.5%）-5.8%Calculated from the two disclosed figures
Investment amount by sectorField M&A and Alliances / Amount Not disclosed
Key initiatives
01Expand the user base
02Expansion of service offerings
03Promoting Global Expansion
Plan assumptionsThe online healthcare market is expected to continue expanding at a CAGR of 15% or more., The B2C e-commerce market for physical goods grew by approximately 3.7% to 4.8% year on year through 2024., Legislative amendments related to online medical care and medication guidance, revisions to medical service fees, and amendments to the Act on the Protection of Personal Information are concentrated in 2026.
Segment targetSegment Medical Care Sales business / Net Sales 5,283 (actual for the fiscal year ending May 2026) → 6,000 (plan for the fiscal year ending May 2027) / Operating profit 483 (actual for the fiscal year ending May 2026) → 815 (plan for the fiscal year ending May 2027), Segment Healthcare Sales business / Net Sales 5,383 (actual for the fiscal year ending May 2026) → 6,200 (plan for the fiscal year ending May 2027) / Operating profit ▲44 (actual for the fiscal year ending May 2026) → 310 (plan for the fiscal year ending May 2027), Segment Healthcare Marketing business / Net Sales 11,568 (actual for the fiscal year ending May 2026) → 14,300 (plan for the fiscal year ending May 2027) / Operating profit 236 (actual for the fiscal year ending May 2026) → 525 (plan for the fiscal year ending May 2027)
Non-financial targetsIndicator name Population coverage / Target value 100% / Timing Future
Size of the Target MarketMarket Global telemedicine market / Dimensions 15.2 (2020) → 60.1 (2028 forecast) / Growth rate CAGR of 15% or more / Source The Insight Partners, “Telemedicine Market,” October 2021, Market B2C e-commerce market for physical goods / Dimensions 26.1 (2024) / Growth rate Not disclosed / Source Ministry of Economy, Trade and Industry, "FY2024 Survey of the Electronic Commerce Market", Market Health Food Market / Dimensions 9,079 (2026 forecast) / Growth rate Not disclosed / Source 株式会社矢野経済研究所, “2026 Edition: Current Status and Outlook for the Health Food Market — Market Research Report”, Market Over-the-counter drug market / Dimensions 7,160 (2025 estimate) / Growth rate Not disclosed / Source 株式会社富士経済, “OTC Drug Databook 2025–2026”, Market Internet advertising market / Dimensions 40,459 (2025) / Growth rate Not disclosed / Source Dentsu, “Advertising Expenditures in Japan for 2025”
Reason for revision or withdrawal
Following the revision of the pricing structure, the proportion of higher-margin revenue, including monthly usage fees (recurring revenue) and usage-based charges, has increased. The company continues to prioritize advertising efficiency and the quality of profit over the quantity of revenue. Favorable market conditions, the pricing revision and stronger alliances have driven a sharp increase in revenue from the SOKUYAKU business, which is strongly leading profit growth.
| Item | Details |
|---|---|
| Plan name | Medium-Term Management Plan |
| Plan period | Fiscal years ending May 2025 to May 2028 (the fiscal years ending May 2025 and May 2026 are actual results; the fiscal years ending May 2027 and May 2028 are projections) |
| Progress against the plan | Partially revised |
| Sales Target | 28,000 (fiscal year ending May 2027, medium-term management plan); 33,000 (fiscal year ending May 2028) → 26,500 (fiscal year ending May 2027, current plan); 33,000 (fiscal year ending May 2028, unchanged) |
| Operating profit target | 1,000 (fiscal year ending May 2027, medium-term management plan); 1,700 (fiscal year ending May 2028) → 1,050 (fiscal year ending May 2027, current plan); 1,700 (fiscal year ending May 2028, unchanged) |
| Operating profit margin target | Not disclosed → 4.0% (plan for the fiscal year ending May 2027) |
| Net income target | Not disclosed → 550 (plan for the fiscal year ending May 2027) |
| Investment amount by sector | Field M&A and Alliances / Amount Not disclosed |
| Segment target | Segment Medical Care Sales business / Net Sales 5,283 (actual for the fiscal year ending May 2026) → 6,000 (plan for the fiscal year ending May 2027) / Operating profit 483 (actual for the fiscal year ending May 2026) → 815 (plan for the fiscal year ending May 2027), Segment Healthcare Sales business / Net Sales 5,383 (actual for the fiscal year ending May 2026) → 6,200 (plan for the fiscal year ending May 2027) / Operating profit ▲44 (actual for the fiscal year ending May 2026) → 310 (plan for the fiscal year ending May 2027), Segment Healthcare Marketing business / Net Sales 11,568 (actual for the fiscal year ending May 2026) → 14,300 (plan for the fiscal year ending May 2027) / Operating profit 236 (actual for the fiscal year ending May 2026) → 525 (plan for the fiscal year ending May 2027) |
| Non-financial targets | Indicator name Population coverage / Target value 100% / Timing Future |
| Plan assumptions | The online healthcare market is expected to continue expanding at a CAGR of 15% or more., The B2C e-commerce market for physical goods grew by approximately 3.7% to 4.8% year on year through 2024., Legislative amendments related to online medical care and medication guidance, revisions to medical service fees, and amendments to the Act on the Protection of Personal Information are concentrated in 2026. |
| Key initiatives | Expand the user base, Expansion of service offerings, Promoting Global Expansion |
| Results under the previous plan | Revenue of 23,600, EBITDA of 1,015 and operating profit of 327 (initial forecasts for the fiscal year ending May 2026) → Revenue of 22,235, EBITDA of 964 and operating profit of 312 (actual results for the fiscal year ending May 2026)（Achievement rates: revenue 94.2%, EBITDA 95.0% and operating profit 95.5%） |
| Reason for revision or withdrawal | Following the revision of the pricing structure, the proportion of higher-margin revenue, including monthly usage fees (recurring revenue) and usage-based charges, has increased. The company continues to prioritize advertising efficiency and the quality of profit over the quantity of revenue. Favorable market conditions, the pricing revision and stronger alliances have driven a sharp increase in revenue from the SOKUYAKU business, which is strongly leading profit growth. |
| Size of the Target Market | Market Global telemedicine market / Dimensions 15.2 (2020) → 60.1 (2028 forecast) / Growth rate CAGR of 15% or more / Source The Insight Partners, “Telemedicine Market,” October 2021, Market B2C e-commerce market for physical goods / Dimensions 26.1 (2024) / Growth rate Not disclosed / Source Ministry of Economy, Trade and Industry, "FY2024 Survey of the Electronic Commerce Market", Market Health Food Market / Dimensions 9,079 (2026 forecast) / Growth rate Not disclosed / Source 株式会社矢野経済研究所, “2026 Edition: Current Status and Outlook for the Health Food Market — Market Research Report”, Market Over-the-counter drug market / Dimensions 7,160 (2025 estimate) / Growth rate Not disclosed / Source 株式会社富士経済, “OTC Drug Databook 2025–2026”, Market Internet advertising market / Dimensions 40,459 (2025) / Growth rate Not disclosed / Source Dentsu, “Advertising Expenditures in Japan for 2025” |
| Publication date | 31 August 2026 |
Items this document does not state (9)
ROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company expects profit growth from favorable market conditions, the revision of SOKUYAKU’s pricing structure and stronger alliances, while prioritizing advertising efficiency and the quality of profit over the quantity of revenue.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.